Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Current Deferred Revenue (2019 - 2025)

Burning Rock Biotech has reported Current Deferred Revenue over the past 7 years, most recently at $15.2 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 7.38% year-over-year to $15.2 million; the TTM value through Dec 2025 reached $15.2 million, down 7.38%, while the annual FY2025 figure was $15.4 million, 4.54% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $15.2 million at Burning Rock Biotech, up from $15.0 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $25.1 million in Q1 2022 and troughed at $13.9 million in Q1 2021.
  • A 5-year average of $18.6 million and a median of $17.9 million in 2024 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: soared 99.05% in 2021 and later fell 21.4% in 2024.
  • Year by year, Current Deferred Revenue stood at $22.3 million in 2021, then dropped by 7.11% to $20.8 million in 2022, then decreased by 12.66% to $18.1 million in 2023, then fell by 9.47% to $16.4 million in 2024, then decreased by 7.38% to $15.2 million in 2025.
  • Business Quant data shows Current Deferred Revenue for BNR at $15.2 million in Q4 2025, $15.0 million in Q3 2025, and $14.4 million in Q2 2025.